Oncotarget

Research Perspectives:

INPP4B: the New Kid on the PI3K Block

Irina U. Agoulnik _, Myles C. Hodgson, Wayne A. Bowden and Michael M. Ittmann

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2011; 2:321-328. https://doi.org/10.18632/oncotarget.260

Metrics: PDF 3255 views  |   HTML 3745 views  |   ?  


Abstract

Irina U. Agoulnik1, Myles C. Hodgson1, Wayne A. Bowden1, Michael M. Ittmann2

1 Herbert Wertheim College of Medicine, Miami, FL

2 Baylor College of Medicine, Houston, TX

Keywords: cancer, PI3K, phosphatase, PTEN, tumor suppressor, oncoprotein, oncotarget

Received: April 6, 2011; Accepted: April 10, 2011; Published: April 10, 2011;

Correspondence:

Irina Agoulnik, e-mail:

Abstract

Dysregulation of phosphatidyl inositol signaling occurs in many cancers and other disorders. The lipid and protein phosphatase, PTEN (Phosphatase and Tensin homology protein on chromosome 10), is a known tumor suppressor whose function is frequently lost in various malignancies due to mutations in the coding region or genomic deletions. Recently, another lipid phosphatase, Inositol Polyphosphate 4-phosphatase type II (INPP4B), has emerged as a potential tumor suppressor in prostate, breast, and ovarian cancers and possibly in leukemia. We will review its structure and function, crosstalk with androgen receptor signaling, and regulation of INPP4B expression, as well as existing data about its role in cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 260